204 related articles for article (PubMed ID: 19725582)
1. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance.
Zhou J; Geng G; Shi Q; Sauriol F; Wu JH
J Med Chem; 2009 Sep; 52(17):5546-50. PubMed ID: 19725582
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
Zhou J; Liu B; Geng G; Wu JH
Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
[TBL] [Abstract][Full Text] [Related]
3. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
4. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
[TBL] [Abstract][Full Text] [Related]
5. Syntheses and potential anti-prostate cancer activities of ionone-based chalcones.
Zhou J; Geng G; Batist G; Wu JH
Bioorg Med Chem Lett; 2009 Feb; 19(4):1183-6. PubMed ID: 19138519
[TBL] [Abstract][Full Text] [Related]
6. 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
Wakabayashi K; Imai K; Miyachi H; Hashimoto Y; Tanatani A
Bioorg Med Chem; 2008 Jul; 16(14):6799-812. PubMed ID: 18571420
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
Goto T; Ohta K; Fujii S; Ohta S; Endo Y
J Med Chem; 2010 Jul; 53(13):4917-26. PubMed ID: 20521823
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring.
Ohta K; Goto T; Fijii S; Suzuki T; Ohta S; Endo Y
Bioorg Med Chem; 2008 Sep; 16(17):8022-8. PubMed ID: 18707892
[TBL] [Abstract][Full Text] [Related]
10. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Zhou J; Geng G; Wu JH
Invest New Drugs; 2010 Jun; 28(3):291-8. PubMed ID: 19390783
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel androgen receptor antagonists with sterically bulky icosahedral carboranes.
Goto T; Ohta K; Suzuki T; Ohta S; Endo Y
Bioorg Med Chem; 2005 Dec; 13(23):6414-24. PubMed ID: 16099660
[TBL] [Abstract][Full Text] [Related]
13. Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands.
Wakabayashi K; Miyachi H; Hashimoto Y; Tanatani A
Bioorg Med Chem; 2005 Apr; 13(8):2837-46. PubMed ID: 15781394
[TBL] [Abstract][Full Text] [Related]
14. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
15. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
16. 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor.
Muddana SS; Price AM; MacBride MM; Peterson BR
J Med Chem; 2004 Oct; 47(21):4985-8. PubMed ID: 15456242
[TBL] [Abstract][Full Text] [Related]
17. Potent androgen antagonists based on carborane as a hydrophobic core structure.
Fujii S; Goto T; Ohta K; Hashimoto Y; Suzuki T; Ohta S; Endo Y
J Med Chem; 2005 Jul; 48(14):4654-62. PubMed ID: 16000001
[TBL] [Abstract][Full Text] [Related]
18. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.
Hamann LG; Higuchi RI; Zhi L; Edwards JP; Wang XN; Marschke KB; Kong JW; Farmer LJ; Jones TK
J Med Chem; 1998 Feb; 41(4):623-39. PubMed ID: 9484511
[TBL] [Abstract][Full Text] [Related]
20. Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate.
Cogan PS; Koch TH
J Med Chem; 2003 Nov; 46(24):5258-70. PubMed ID: 14613328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
